Press releases
GSK supports BMJ commitment on clinical trial data transparency
GlaxoSmithKline today responded to the news that the BMJ will only publish scientific papers where there is a commitment to make the relevant anonymised patient level data available on reasonable request.
Results announcement for the third quarter 2012
GSK delivers Q3 core EPS of 26.5p and dividend of 18p.
GSK announces start of Phase lll programme for mepolizumab in severe refractory asthma
GlaxoSmithKline plc (GSK) today announced the start of a Phase III programme to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist, as adjunctive therapy in severe uncontrolled refractory asthma.
Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio
ViiV Healthcare Ltd and Shionogi & Co., Ltd. today announced that they have entered into an agreement substantially revising their integrase inhibitor relationship.
Results from five phase III studies presented for GSK’s two candidate quadrivalent influenza vaccines
GSK today announced that results from five Phase III studies investigating its two candidate quadrivalent influenza vaccines were presented at the Influenza Vaccines for the World congress in Valencia, Spain and the Infectious Diseases week congress in San Diego, USA in October.
GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges
Speaking at a meeting hosted by the Wellcome Trust in London today, GSK CEO Sir Andrew Witty will outline new steps to build on the encouraging signs of progress resulting from GSK’s ‘open innovation’ approach to R&D, designed to help develop new solutions for the world’s most serious health challenges.
Millions of children in Pakistan to be protected against pneumococcal disease with GSK’s Synflorix
GlaxoSmithKline (GSK) welcomes today’s announcement from the GAVI Alliance that its pneumococcal vaccine, SynflorixTM, is to be introduced into the national immunisation programme in Pakistan.
Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV
Shionogi-ViiV Healthcare LLC today announced that the phase III data required for initial regulatory filings of the investigational integrase inhibitor dolutegravir in adults infected with HIV are in house.
Head-to-head study of GSK’s Votrient® (pazopanib) vs sunitinib in advanced renal cell carcinoma meets primary endpoint; findings presented at ESMO 2012 Congress
GlaxoSmithKline (GSK) plc announced today that the pivotal Phase III study COMPARZ (COMParing the efficacy, sAfety and toleRability of paZopanib vs. sunitinib) has met its primary endpoint.
GlaxoSmithKline plc announces changes to its Board and Committees
GlaxoSmithKline plc today announces the following changes to its Board and Committee structure.
